Iterum Therapeutics Files 8-K on Shareholder Votes
Ticker: ITRM · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: ITRM
TL;DR
Iterum Therapeutics held a shareholder vote, details to follow.
AI Summary
Iterum Therapeutics plc filed an 8-K on October 8, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented to shareholders, but it serves as a formal notification of such an event.
Why It Matters
This filing indicates that Iterum Therapeutics held a meeting where shareholders voted on important company matters, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is a procedural notification of a shareholder vote without immediate financial or operational disclosures.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- October 08, 2024 (date) — Date of Report
FAQ
What specific matters were submitted for a vote by Iterum Therapeutics plc's security holders?
The provided filing (Form 8-K) does not specify the exact matters submitted for a vote by security holders. It only states that such matters were presented.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is October 08, 2024.
What is the principal executive office address for Iterum Therapeutics plc?
The principal executive office address for Iterum Therapeutics plc is Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, Ireland.
What is the company's telephone number as listed in the filing?
The company's telephone number, including area code, is +353 1 6694820.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 14 · Accepted 2024-10-08 09:15:34
Key Financial Figures
- $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
Filing Documents
- itrm-20241008.htm (8-K) — 42KB
- 0000950170-24-113413.txt ( ) — 157KB
- itrm-20241008.xsd (EX-101.SCH) — 26KB
- itrm-20241008_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On October 8, 2024, Iterum Therapeutics plc (the " Company ") held an extraordinary general meeting, at which the Company's shareholders voted on the following proposal, which is described in the Company's definitive proxy statement, filed with the Securities and Exchange Commission on August 14, 2024. Proposal: Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders. The shareholders approved the grant to the board of directors of authority under Irish law to allot shares (including rights to acquire such shares) for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance. This proposal required the affirmative vote of the holders of ordinary shares representing at least 75% of the votes cast on the matter to be approved. The results of the shareholders' vote were as follows: For Against Abstain Broker Non-Votes 9,785,120 3,103,525 133,633 * * No broker non-votes arose in connection with the Proposal due to the fact the matter was considered "routine" under New York Stock Exchange rules.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: October 8, 2024 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer